SUCCESSFUL THERAPY OF CLOSTRIDIUM DIFFICILE INFECTION WITH FECAL MICROBIOTA TRANSPLANTATION

被引:2
|
作者
Konturek, P. C. [1 ]
Koziel, J. [2 ]
Dieterich, W. [3 ]
Haziri, D. [1 ]
Wirtz, S. [3 ]
Glowczyk, I. [2 ]
Konturek, K. [1 ]
Neurath, M. F. [3 ]
Zopf, Y. [3 ]
机构
[1] Univ Jena Saalfeld Saale, Teaching Hosp, Thuringia Clin Saalfeld, Dept Med, Saalfeld Saale, Germany
[2] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Microbiol, Krakow, Poland
[3] Univ Erlangen Nurnberg, Dept Med 1, Erlangen, Germany
来源
JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY | 2016年 / 67卷 / 06期
关键词
Clostridum difficile infection; fecal microbiota therapy; gut microbiota; C-reactive protein; fecal calprotectin; LL-37; interleukin-1; beta; interleukin-6; interleukin-8; interleukin-12; tumor necrosis factor-alpha; fluorescence-activated cell sorting; LONG-TERM OUTCOMES; GUT MICROBIOTA; RECURRENT; MULTICENTER; PREDICTORS; HEALTH;
D O I
暂无
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Clostridium difficile infection (CDI) is the most common cause of infectious diarrhea and represents an important burden for healthcare worldwide. Symptoms of severe CDI include watery, foul-smelling diarrhea, peripheral leucocytosis, increased C-reactive protein (CRP), acute renal failure, hypotension and pseudomembranous colitis. Recent studies indicate that the main cause of CDI is dysbiosis, an imbalance in the normal gut microbiota. The restoration of a healthy gut microbiota composition via fecal microbiota transplantation (FMT) recently became more popular. The aim of the present study was to assess the effect of FMT on the healing of CDI and to analyze the changes in the level of pro-inflammatory markers (C-reactive protein, fecal calprotectin) and pro-inflammatory cytokines. Eighteen patients with CDI were included in our study (6 males and 12 females) with recurrent and/or severe CDI. The FMT was performed in 17 patients using colonoscopy, including 16 patients receiving a one-time FMT and 1 patient who needed 2 additional FMTs. One patient was treated with a single round of FMT using push-and-pull enteroscopy. In all CDI patients, before and 3 weeks after FMT, the following parameters were analyzed: C-reactive protein, fecal calprotectin, and plasma interleukin (IL)-6, IL-8 and IL-12, and tumor necrosis factor-alpha (TNF-alpha). In addition, the plasma level of LL-37, a cathelicidine peptide was assessed by fluorescence-activated cell sorting (FACS) before and 3 months after FMT. Finally, in 7 patients a microbiome analysis was performed by sequencing of 16SrRNA in stool probes obtained before and 3 weeks after FMT. The healing rate of CDI was 94%. In all successfully treated patients no recurrent CDI was observed during follow-up (16 months). The serum level of pro-inflammatory cytokines (TNF-alpha, IL 1[3, IL-6, IL-8 and IL-12) significantly decreased after FMT. Similarly, CRP and fecal calprotectin normalized after FMT. 3 months after FMT a significant increase of LL-37 in the plasma of successfully treated patients was monitored. The sequencing analysis demonstrated an elevated abundance of beneficial bacterial species such as Lactobacillaceae, Ruminococcaceae, Desulfovibrionaceae, Sutterellaceae and Porphyromonodacea after FMT. No serious side effects were observed. We concluded that FMT represented a very effective and safe treatment of recurrent and/or severe CDI and led to favorable shifts in the composition of gut microbiome.
引用
收藏
页码:859 / 866
页数:8
相关论文
共 50 条
  • [1] SUCCESSFUL THERAPY OF CLOSTRIDIUM DIFFICILE INFECTION WITH FECAL MICROBIOTA TRANSPLANTATION
    Konturek, Peter C.
    Dieterich, Walburga
    Neurath, Markus
    Zopf, Yurdaguel
    GASTROENTEROLOGY, 2017, 152 (05) : S341 - S341
  • [2] Successful Fecal Microbiota Transplantation as an Initial Therapy for Clostridium difficile Infection on an Outpatient Basis
    Tanaka, Takamasa
    Kato, Haru
    Fujimoto, Takushi
    INTERNAL MEDICINE, 2016, 55 (08) : 999 - 1000
  • [3] Fecal Microbiota Transplantation for Clostridium difficile Infection
    Armstrong, Matthew J.
    Pathmakanthan, Shrikanth
    Iqbal, Tariq H.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (07): : 725 - 726
  • [4] Fecal Fixation: Fecal Microbiota Transplantation for Clostridium difficile Infection
    Johnson, Stuart
    Gerding, Dale N.
    CLINICAL INFECTIOUS DISEASES, 2017, 64 (03) : 272 - 274
  • [5] Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection
    Brandt, Lawrence J.
    Reddy, Sheela S.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2011, 45 : S159 - S167
  • [6] Fecal Microbiota Transplantation for the Management of Clostridium difficile Infection
    Rao, Krishna
    Young, Vincent B.
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2015, 29 (01) : 109 - +
  • [7] Fecal microbiota transplantation for management of Clostridium difficile infection
    Vaishnavi C.
    Indian Journal of Gastroenterology, 2014, 33 (4) : 301 - 307
  • [8] Fecal Microbiota Transplantation for Clostridium difficile Infection Reply
    Youngster, Ilan
    Hohmann, Elizabeth L.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (07): : 726 - 726
  • [9] Fecal Microbiota Transplantation for Primary Clostridium difficile Infection
    Juul, Frederik E.
    Garborg, Kjetil
    Bretthauer, Michael
    Skudal, Hilde
    Oines, Mari N.
    Wiig, Havard
    Rose, Oystein
    Seip, Birgitte
    Lamont, J. Thomas
    Midtvedt, Tore
    Valeur, Jorgen
    Kalager, Mette
    Holme, Oyvind
    Helsingen, Lise
    Loberg, Magnus
    Adami, Hans-Olov
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (26): : 2535 - +
  • [10] Fecal Microbiota Transplantation for the Management of Clostridium difficile Infection
    Paknikar, Raghavendra
    Pekow, Joel
    SURGICAL INFECTIONS, 2018, 19 (08) : 785 - 791